Moderna's $1 Billion Revenue Forecast Cut Sends Stock Plummeting Over 20%

Core Viewpoint - Shares of pharmaceutical giant Moderna (MRNA) experienced a significant decline after the company revised its 2025 revenue forecast downward by $1 billion [1][4]. Revenue Forecast - Moderna now projects its revenue for the current year to be between $1.5 billion and $2.5 billion, a decrease from the previous estimate of $2.5 billion to $3.5 billion made in September [2]. - The company anticipates that most of this revenue will be generated in the second half of the year, primarily from sales of its Covid-19 and respiratory syncytial virus (RSV) vaccines [2][4]. Expense Management - Moderna plans to implement a $1 billion reduction in expenses for the current year, with an additional $500 million cut expected in 2026 [2]. Stock Performance - The stock price of Moderna fell over 20% intraday to $33.44, effectively negating gains made the previous week following the first reported bird-flu death in the U.S. [3]. - Over the past year, Moderna's stock has lost approximately two-thirds of its value and is significantly below its all-time high of nearly $490 reached in August 2021 during the COVID-19 pandemic [3][4].